The role of plasminogen activator inhibitor-1 polymorphism, factor-V-Leiden, and prothrombin-20210 mutations in pulmonary thromboembolism

I. Kivilcim Oguzulgen, Senay Demirtas, Ferda Oner Erkekol, Numan Ekim, Nalan Demir, Numan Numanoglu, Duygu Ozel, Arzu Ulu, Nejat Akar

Research output: Contribution to journalArticlepeer-review

13 Scopus citations

Abstract

Polymorphism in plasminogen activator inhibitor-1 gene is suggested to be associated with an increased risk of venous thromboembolism. The aim of this study was to investigate the association of plasminogen activator inhibitor-1 gene polymorphism and its coexistence with factor-V-Leiden and prothrombin-20210 mutations in pulmonary thromboembolism. The authors investigated plasminogen activator inhibitor-1 4G/5G polymorphism, factor-V-Leiden, and prothrombin-20210 mutations in 143 pulmonary thromboembolism patients and 181 controls. Plasminogen activator inhibitor-1 4G/4G, 4G/5G, and 5G/5G gene polymorphisms and prothrombin-20210 mutations were not different between cases and controls. Factor-V-Leiden mutation was present in 21.0% and 7.7% of the cases and controls, respectively, P =.001. Neither different plasminogen activator inhibitor-1 genotypes and 4G allele nor coexistence of the allele with factor-V-Leiden or prothrombin-20210 was associated with the risk of recurrence. As a result, plasminogen activator inhibitor-1 gene polymorphism or its concomitant presence with mentioned mutations was not found to be associated with increased risk for pulmonary thromboembolism or recurrent disease in this study.

Original languageEnglish (US)
Pages (from-to)73-77
Number of pages5
JournalClinical and Applied Thrombosis/Hemostasis
Volume15
Issue number1
DOIs
StatePublished - Feb 2009
Externally publishedYes

Keywords

  • Factor-V-Leiden
  • Genetics
  • Plasminogen activator inhibitor-1
  • Prothrombin-20210
  • Pulmonary thromboembolism

ASJC Scopus subject areas

  • Hematology

Fingerprint Dive into the research topics of 'The role of plasminogen activator inhibitor-1 polymorphism, factor-V-Leiden, and prothrombin-20210 mutations in pulmonary thromboembolism'. Together they form a unique fingerprint.

Cite this